SAN DIEGO & TOKYO--(BUSINESS WIRE)-- Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that the first presentation of interim data from a global multi-center Phase 2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback